Compare Novartis AG (NVS) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs abrdn Physical Palladium Shares ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while abrdn Physical Palladium Shares ETF trades at $23.31. The key difference: Novartis AG pays a 3.17% dividend while abrdn Physical Palladium Shares ETF pays none, and Novartis AG is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| NVS | PALL | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $168.62 | $37.18 |
52-Week Low | $113.50 | $19.96 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PALL (abrdn Physical Palladium Shares ETF) trades at $22.80, up 0.44% with a bearish technical signal from moving averages. Recent news highlights palladium's underperformance versus other precious metals, though some analysts see current price weakness as a buying opportunity. The ETF underwent a 5-for-1 forward share split on May 18, 2026, which adjusted share count without changing the underlying value.
The outlook for PALL hinges on palladium's supply-demand dynamics and industrial usage. While technical indicators suggest near-term pressure, fundamental factors like supply constraints and potential demand recovery could support prices. Key risks include Federal Reserve policy impacts and global economic conditions affecting industrial demand for palladium.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
